• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    4/19/24 12:31:40 PM ET
    $AEON
    $ANL
    $CCM
    $CDIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEON alert in real time by email

    Gainers

    • Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. The market value of their outstanding shares is at $932.9 million.
    • NKGen Biotech (NASDAQ:NKGN) stock increased by 19.76% to $1.03. The company's market cap stands at $23.4 million. The company's, Q4 earnings came out 3 days ago.
    • Kintara Therapeutics (NASDAQ:KTRA) stock increased by 18.57% to $0.13. The market value of their outstanding shares is at $4.9 million.
    • NeuroMetrix (NASDAQ:NURO) stock moved upwards by 17.26% to $4.28. The company's market cap stands at $8.5 million.
    • Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 17.24% to $0.05. The company's market cap stands at $4.1 million.
    • Adlai Nortye (NASDAQ:ANL) stock moved upwards by 16.33% to $12.39. The company's market cap stands at $457.1 million.

    Losers

    • SeaStar Medical Holding (NASDAQ:ICU) shares decreased by 21.2% to $0.43 during Friday's regular session. The company's market cap stands at $32.0 million. As per the press release, Q4 earnings came out 3 days ago.
    • iSpecimen (NASDAQ:ISPC) stock decreased by 20.81% to $0.33. The company's market cap stands at $3.0 million.
    • AEON Biopharma (AMEX:AEON) shares decreased by 18.35% to $5.34. The market value of their outstanding shares is at $203.5 million.
    • Regencell Bioscience (NASDAQ:RGC) stock declined by 17.63% to $4.3. The company's market cap stands at $55.9 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares declined by 15.6% to $0.92. The market value of their outstanding shares is at $19.8 million.
    • Concord Medical Services (NYSE:CCM) shares declined by 14.25% to $0.5. The market value of their outstanding shares is at $21.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEON
    $ANL
    $CCM
    $CDIO

    CompanyDatePrice TargetRatingAnalyst
    Adlai Nortye Ltd.
    $ANL
    2/13/2026$16.00Neutral → Buy
    H.C. Wainwright
    Adlai Nortye Ltd.
    $ANL
    6/2/2025Buy → Neutral
    H.C. Wainwright
    Adlai Nortye Ltd.
    $ANL
    9/4/2024$9.00Buy
    H.C. Wainwright
    Adlai Nortye Ltd.
    $ANL
    10/24/2023$30.00Overweight
    Cantor Fitzgerald
    AEON Biopharma Inc.
    $AEON
    8/18/2023$18.00Buy
    H.C. Wainwright
    Kintara Therapeutics Inc.
    $KTRA
    1/20/2022$6.00 → $3.00Buy
    HC Wainwright & Co.
    iSpecimen Inc.
    $ISPC
    1/4/2022$20.00Buy
    Craig-Hallum
    iSpecimen Inc.
    $ISPC
    11/22/2021$10.00 → $12.00Buy
    EF Hutton
    More analyst ratings

    $AEON
    $ANL
    $CCM
    $CDIO
    SEC Filings

    View All

    SEC Form DEFA14A filed by iSpecimen Inc.

    DEFA14A - iSpecimen Inc. (0001558569) (Filer)

    3/3/26 4:05:22 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Inc. filed SEC Form 8-K: Leadership Update

    8-K - iSpecimen Inc. (0001558569) (Filer)

    2/23/26 4:30:12 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    2/19/26 8:00:30 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEON
    $ANL
    $CCM
    $CDIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Van Heel Kenneth bought $30,812 worth of shares (35,000 units at $0.88), increasing direct ownership by 243% to 49,400 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/28/25 5:28:58 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AEON
    $ANL
    $CCM
    $CDIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adlai Nortye Ltd. upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00

    2/13/26 9:51:23 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adlai Nortye Ltd. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adlai Nortye Ltd. from Buy to Neutral

    6/2/25 11:24:27 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Adlai Nortye Ltd. with a new price target

    H.C. Wainwright initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $9.00

    9/4/24 7:16:56 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $ANL
    $CCM
    $CDIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

    IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL. The abstract builds upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%–99.3% peptide sequence coverage across BoNT/A1 and associated accessory protein

    3/5/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

    DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of its analysis of the data. "The early results from the SAVE Regis

    3/5/26 8:20:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEON
    $ANL
    $CCM
    $CDIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO, CSO, and Corp Secretary Wilson Alexander Blair was granted 2,179,372 shares, increasing direct ownership by 59,988% to 2,183,005 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    3/5/26 6:07:56 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRINCIPAL ACCOUNTING OFFICER Sy Jennifer was granted 1,500,925 shares, increasing direct ownership by 597,978% to 1,501,176 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    3/5/26 6:06:25 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT & CEO Bancroft Robert E. was granted 3,000,000 shares, increasing direct ownership by 1,694% to 3,177,103 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    2/19/26 8:40:27 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $ANL
    $CCM
    $CDIO
    Leadership Updates

    Live Leadership Updates

    View All

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

    SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th

    12/3/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AEON
    $ANL
    $CCM
    $CDIO
    Financials

    Live finance-specific insights

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

    – FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON's balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE

    11/14/25 8:30:00 AM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance RegistryNew clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollmentStrengthened the balance sheet, raising $12.4 million to fund future operationsWebcast call today at 4:30 p.m. Eastern Time DENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure

    11/13/25 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $AEON
    $ANL
    $CCM
    $CDIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by AEON Biopharma Inc.

    SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

    11/14/24 5:05:14 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Veterinary Partners Inc.

    SC 13G/A - INSPIRE VETERINARY PARTNERS, INC. (0001939365) (Subject)

    10/11/24 4:05:57 PM ET
    $IVP
    Farming/Seeds/Milling
    Consumer Staples